Today’s pharmaceutical industry is failing most Americans. The structure of laws, regulations, and institutions that shape corporate decision-making drive runaway profits rather than improve patient health. Transforming this broken system requires using the tools of government in expansive ways—a “one-two punch”—by reining in the industry’s extractive practices through stiffer market regulation and deploying the power

In the wake of President Trump’s election in 2016, my friends and I at the George Washington University (GW) were anxious about health insurance. We worried that Trump and a Republican legislature might overturn the entire Affordable Care Act. A loss of protections allowing young people to stay on their parents’ health insurance until age

Health care—and the prospect of a single-payer system—has gotten a lot of attention at the national level and in presidential debates this year. And for good reason: The costs of health care are consistently rising faster than the economy overall, and households are bearing those increased costs through growing premiums and deductibles. That means many

Today’s pharmaceutical industry is failing most Americans. Every day, a new story emerges about an outrageous price spike for a lifesaving drug, a fraud perpetrated on the American people in the name of profit, or the revolving door of administration officials entering an agency from a drug company or leaving to go to one—a practice

Did Marketplace Coverage Really Offer Financial Protection? Financial Gains from the Affordable Care Act’s Private Insurance Policies for the Previously Uninsured While the Affordable Care Act (ACA) expanded health coverage to millions of Americans, more than half of the people eligible for the law’s private insurance marketplace remained uninsured. Today, most of those who were

FOR IMMEDIATE RELEASE: July 11, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org Rising Number of Hospital Mergers and Closures in Rural America Hurting Women’s Health, Economic Well-Being Roosevelt Institute documents adverse effects of market power crisis An issue brief released today by the Roosevelt Institute finds that corporate consolidation within America’s rural hospital sector is harming both

Structural problems in the health care and hospital industries are specifically hurting women in rural America, both as patients and as workers. In a new Roosevelt issue brief, Andrea Flynn, Rakeen Mabud, and Emma Chessen explore some of the industry-wide shifts that have occurred in rural areas over the last several decades. They then describe the

FOR IMMEDIATE RELEASE: June 19, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org The High Cost of Shareholder Power in Big Pharma New Roosevelt brief illustrates the magnitude of Big Pharma spending on shareholders NEW YORK, NY – At a time when Americans pay record prices for medications, pharmaceutical companies generate record profits devoted largely to rewarding shareholders

Despite Big Pharma’s claim that high-cost medicines are the price society must pay for innovation, recent research provides ample evidence that overpriced medicines are not necessary for the industry to find cures or revolutionize. Rather, high-cost and low-quality medicines are the price patients pay for an industry that prioritizes profit-seeking over public health. Like all

FOR IMMEDIATE RELEASE: May 22, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org Capturing the Government: Big Pharma’s Take Over of Policymaking New brief explores how drug companies influence policymakers and the resulting harm in patient outcomes Today, the Roosevelt Institute released the issue brief, “The Cost of Capture: How the Pharmaceutical Industry has Corrupted Policy Makers and